Jobless Claims Remain Low Signaling Continued Labor Market Strength
Could the Fed Raise Rates in July Yardeni Warns of Bond Vigilante Pressure on Incoming Chair Warsh
UOB Faces High Court Criticism Over Inconsistent Legal Stance on Late Mortgage Charges
Diversified Energy Acquires Permian Basin Natural Gas Player Maverick Resources
China Calls for APEC Economic Cooperation as Commerce Minister Skips Meeting Over Urgent Official Business
National Retail Federation Projects 44 Growth in US Retail Sales for 2026
ARMK Q1 2026 Earnings EPS Slightly Misses Estimates Amid Mixed Market Reaction
XBIO Q2 2025 Earnings Loss Narrows Despite No Revenue as Biotech Advances Pipeline
Novagold Resources NG Q1 2026 Earnings Narrower Loss Drives 74 Stock Gain
General Motors Q1 2026 Earnings Strong EPS Beat Drives Stock Higher
NeoVolta NEOV Q1 2026 Earnings EPS Beats Estimates Despite Revenue Absence Stock Drops 2364
SAIC Q1 2026 Earnings Strong EPS Beat Driven by Operational Efficiency
Range Capital Acquisition Corp II Warrants RNGTW Flat at 032 as Warrants Trade Near Support
Unicycive Therapeutics UNCY Surges 59 as Shares Test Key Resistance
CVD Equipment Corporation CVV Surges Over 4 Key Levels to Watch
Regencell Bioscience RGC Edges Higher Approaches Key Resistance Level
InvenTrust Properties IVT Edges Higher Testing Resistance Levels as REIT Sector Shows Stability
Lixte Biotechnology LIXT Holds Near Support After Slight Decline
Better Home Finance Holding Warrants BETRW Slide Sharply as Support Level Under Threat
Codere Online CDRO Edges Higher Testing Key Resistance Zone
Ensysce Biosciences ENSC Declines Further Tests Key Support Near 029
PMGC Holdings Inc ELAB Pulls Back 23 as Sellers Test Support Near 162
Cerus Corporation CERS Consolidates Near 273 as Support and Resistance Levels Hold
Kevin Warsh Vows ReformOriented Approach as New Federal Reserve Chair
RYTM Q1 2026 Earnings NarrowerthanExpected Loss Drives Positive Stock Reaction
Optical Cable Corporation OCC Surges Over 10 as Fiber Optic Demand Drives Momentum
JANX Q1 2026 Earnings NarrowerthanExpected Loss Buoys Biotech Sentiment
PRE Q4 2025 Earnings EPS Falls Sharply Short of Expectations Amid Transition
Visa Q1 2026 Earnings EPS Beats Estimates by 482 as Payments Volume Remains Resilient
YSS Q1 2026 Earnings EPS Misses Estimates by Wide Margin as PreRevenue Stage Continues
LTRN Q1 2026 Earnings NarrowerThanExpected Loss Highlights Operational Discipline Amid No Revenue
CLDX Q1 2026 Earnings Slight EPS Miss as DevelopmentStage Biotech Continues NoRevenue Phase
PATK Q1 2026 Earnings EPS Surpasses Estimates Amid Strong Operational Execution